Xamoterol in sinus node disease.
A pharmacological alternative to pace-maker implantation would be useful in some patients with sinoatrial disorder particularly since the single lead ventricular system usually fitted has disadvantages. Xamoterol, a cardioselective beta-receptor partial agonist, has been shown to increase heart rate both in animals and in man. We, therefore, studied the effects of Xamoterol in patients with sinoatrial disease in a double blind, cross-over trial in 10 patients. Mean heart rates and number and duration of pauses were compared during the treatment phases of the trial with Holter monitoring. Mean heart rates were significantly increased between 01:00 h and 05:00 h (P < or = 0.02) and between 05:00 h and 09:00 h (P < or = 0.01) on Xamoterol. The number of sinus pauses were eliminated or reduced on Xamoterol in six patients, but there was an increased frequency in three patients. Xamoterol, therefore, does increase the heart rate and reduce the number of pauses in sinoatrial disorder, but only in some patients.
Avery
P G
PG
Department of Cardiology, Royal Devon and Exeter Hospital, Wonford, UK.
Small
J
J
Shaw
D B
DB
D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D015716:Electrocardiography, Ambulatory; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012804:Sick Sinus Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D016037:Single-Blind Method; D012848:Sinoatrial Block / Q000188:drug therapy* / Q000503:physiopathology; D017307:Xamoterol / Q000627:therapeutic use*
D017307:Xamoterol